Parkinson's disease and skin

Keyphrases

• Parkinson's Disease 100%
• Neurodegenerative Diseases 33%
• Rosaceae 33%
• Skin Diseases 33%
• Recent Advances 33%
• Delivery System 33%
• Melanoma 33%
• Drug Discovery 33%
• Patients with Parkinson's Disease 33%
• Disease Pathogenesis 33%
• Systemic Side Effects 33%
• Stem Cell Therapy 33%
• Bullous Pemphigoid 33%
• Pathophysiological Mechanisms 33%
• Deep Brain Stimulation 33%
• Stem Cell-derived 33%
• Dopamine Agonist 33%
• Alpha-synuclein (α-syn) 33%
• Sweating 33%
• Skin Fibroblasts 33%
• Antiparkinsonian Drugs 33%
• Induced Pluripotent Stem Cells (iPSCs) 33%
• Peripheral Tissues 33%
• Amantadine 33%
• Dermatological Diseases 33%
• Catechol-O-methyltransferase Inhibitors 33%
• Carbidopa-levodopa 33%
• Anti-Parkinson 33%
• Research-based 33%
• Seborrheic Dermatitis 33%
• Rotigotine 33%
• Subcutaneous Apomorphine 33%
• Levodopa-carbidopa Intestinal Gel 33%
• Cell Diagnostics 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Parkinson's Disease 100%
• Antiparkinson Agent 50%
• Carbidopa Plus Levodopa 50%
• Iatrogenic Disease 50%
• Diseases 25%
• Dopamine Receptor Stimulating Agent 25%
• Melanoma 25%
• Synuclein 25%
• Drug Discovery 25%
• Apomorphine 25%
• Catechol 25%
• Amantadine 25%
• Dermatological Agent 25%
• Methyltransferase Inhibitor 25%
• Skin Disease 25%
• Seborrheic Dermatitis 25%
• Rotigotine 25%
• Rosacea 25%
• Bullous Pemphigoid 25%
• Side Effect 25%